Post
Magazine: The journey of first generics
In a 2022 annual report, the US Food and Drug Administration’s (FDA) Office of Generic Drugs stated it had approved …
Avadel Pharmaceuticals launches excessive daytime sleepiness therapy in US
Avadel Pharmaceuticals has introduced LUMRYZ (sodium oxybate) for commercial use in the US to treat cataplexy (excessive daytime sleepiness, or …
Selvita and the University of Oxford join forces to tackle Parkinson’s disease
The Polish drug discovery and service provider Selvita has announced a new collaboration with the University of Oxford to advance …
ASCO 2023: Summit Therapeutics plans to rise with bispecific NSCLC data
Summit Therapeutics has announced data for its novel investigational bispecific antibody, ivonescimab, known as SMT112 or AK112 in a non-small …
ASCO 2023: Research backs chemo-only approach for some rectal cancer patients
Results unveiled at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting indicate that some patients with locally advanced …
Subscribe to our Newsletter
Get industry leading news, data and analysis delivered to your inbox
ITM raises $273 million to fund radionuclide therapy pipeline
ITM (Isotope Technologies Munich) has announced a €255 million ($273.16 million) equity investment funding raise. According to ITM’s CEO Steffen …
Simurosertib by Millennium Pharmaceuticals for Rectal Cancer: Likelihood of Approval
Simurosertib is under clinical development by Millennium Pharmaceuticals and currently in Phase I for Rectal Cancer. According to GlobalData, Phase …
IXC-103 by Ixchel Pharma for Friedreich Ataxia: Likelihood of Approval
IXC-103 is under clinical development by Ixchel Pharma and currently in Phase I for Friedreich Ataxia. According to GlobalData, Phase …
BGB-3245 by MapKure for Bile Duct Cancer (Cholangiocarcinoma): Likelihood of Approval
BGB-3245 is under clinical development by MapKure and currently in Phase I for Bile Duct Cancer (Cholangiocarcinoma). According to GlobalData, …
BGB-3245 by MapKure for Endometrial Cancer: Likelihood of Approval
BGB-3245 is under clinical development by MapKure and currently in Phase I for Endometrial Cancer. According to GlobalData, Phase I …
Telitacicept by RemeGen for Antiphospholipid Syndrome: Likelihood of Approval
Telitacicept is under clinical development by RemeGen and currently in Phase II for Antiphospholipid Syndrome. According to GlobalData, Phase II …
BGB-3245 by MapKure for Melanoma: Likelihood of Approval
BGB-3245 is under clinical development by MapKure and currently in Phase I for Melanoma. According to GlobalData, Phase I drugs …
4D-110 by 4D Molecular Therapeutics for Choroideremia: Likelihood of Approval
4D-110 is under clinical development by 4D Molecular Therapeutics and currently in Phase II for Choroideremia. According to GlobalData, Phase …
Valemetostat by Daiichi Sankyo for Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy: Likelihood of Approval
Valemetostat is under clinical development by Daiichi Sankyo and currently in Phase II for Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy. According …
Valemetostat by Daiichi Sankyo for Follicular Lymphoma: Likelihood of Approval
Valemetostat is under clinical development by Daiichi Sankyo and currently in Phase II for Follicular Lymphoma. According to GlobalData, Phase …